Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenzavirus infections

Autor: Albert D. M. E. Osterhaus, Oliver N. Keene, Frederick G. Hayden, Arthur M. Bohnen, Hilary M. Hirst, D. M. Fleming, Kevin Wightman, Karl G. Nicholson, John J. Treanor, Fred Y. Aoki

Publikováno v: New England Journal of Medicine, 874-881. Massachussetts Medical Society
ISSUE=337;STARTPAGE=874;ENDPAGE=881;ISSN=0028-4793;TITLE=New England Journal of Medicine

Background: The sialic acid analogue zanamivir (GG167) is a selective inhibitor of influenza A and B virus neuraminidases. These viral enzymes are essential for the release of virus from infected cells, and they may also reduce the inactivation of vi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a4f9096afeb49b60954aaf03ea24a15
https://pure.eur.nl/en/publications/4d63d816-c0a1-4a26-95d3-dd785bb1f263